How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,634 results for

Squamous Cell Carcinoma of the Skin

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

13921. Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Head and Neck Cancer

: Not specified Renal: Not specified Cardiovascular: No hypertension (diastolic pressure greater than 100 mmHg) refractory to treatment No symptomatic cardiovascular disease No deep vein thrombosis Other: No other malignancy except cured basal cell skin cancer or carcinoma in situ of the cervix No psychological, familial, sociological, or geographical condition that would preclude study compliance No smoking during study Not pregnant or nursing Fertile patients must use effective contraception PRIOR (...) confirmed squamous cell carcinoma of the oral cavity, larynx, oropharynx, or hypopharynx Stage T1-T4, any N No T1, N0 glottic tumor No nodal disease from unknown primary Previously untreated disease No distant metastases Planned radiotherapy PATIENT CHARACTERISTICS: Age: 18 to 75 Performance status: WHO 0-2 Life expectancy: Not specified Hematopoietic: Hemoglobin greater than 10 g/dL but no greater than 14 g/dL for men Hemoglobin greater than 10 g/dL but no greater than 13.5 g/dL for women Hepatic

2001 Clinical Trials

13922. DX-8951f in Treating Patients With Metastatic Stomach Cancer

adenocarcinoma Lymph node involvement and/or distant metastasis No squamous cell carcinoma, small cell carcinoma, lymphoma, or leiomyosarcoma of the stomach Measurable disease with indicator lesions outside the field of prior radiotherapy At least 20 mm by conventional scan OR At least 10 mm by spiral CT scan Nonmeasurable lesions include the following: Primary tumor Bone lesions Leptomeningeal disease Ascites Pleural/pericardial effusion Inflammatory breast disease Lymphangitis cutis/pulmonitis Cystic (...) Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of exatecan mesylate in treating patients who have metastatic stomach cancer. Condition or disease Intervention/treatment Phase Esophageal Cancer Gastric Cancer Drug: exatecan mesylate Phase 2 Detailed Description: OBJECTIVES: Determine the objective response rate of patients with previously untreated

2001 Clinical Trials

13923. S0011, Gene Therapy & Surgery Followed by Chemo & RT in Newly Diagnosed Cancer of the Mouth or Throat

60 mL/min Other: Magnesium normal (magnesium supplement allowed) No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer in complete remission HIV negative Not pregnant or nursing Patients must use effective barrier contraception and prevent bodily fluid transmission during and for 28 days after Ad5CMV-p53 gene administration PRIOR CONCURRENT THERAPY: Biologic therapy (...) to damage tumor cells. Combining chemotherapy and radiation therapy with the p53 gene may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of gene therapy plus surgery followed by cisplatin and radiation therapy in treating patients who have newly diagnosed resectable stage III or stage IV cancer of the mouth or throat. Condition or disease Intervention/treatment Phase Head and Neck Cancer Biological: Ad5CMV-p53 gene Drug: cisplatin Procedure: conventional surgery Radiation

2001 Clinical Trials

13924. Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer

less than 1.2 mg/dL SGOT less than 60 IU/L Renal: Creatinine less than 1.35 mg/dL Cardiovascular: LVEF normal by echocardiography or MUGA Other: No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix No serious uncontrolled medical condition No uncontrolled psychiatric or addictive disorders Not pregnant or nursing Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified (...) cancer stage IIIC breast cancer inflammatory breast cancer Additional relevant MeSH terms: Layout table for MeSH terms Breast Neoplasms Inflammatory Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Cyclophosphamide Fluorouracil Docetaxel Epirubicin Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents

2001 Clinical Trials

13925. BMS-247550 in Treating Patients With Recurrent Metastatic Stomach Cancer That Has Been Previously Treated With Chemotherapy

information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria DISEASE CHARACTERISTICS: Histologically confirmed recurrent metastatic adenocarcinoma of the stomach or gastroesophageal junction No squamous cell or sarcomatous elements in tumor Previously treated with 1 prior fluoropyrimidine and/or platinum based chemotherapy regimen for metastatic disease OR Recurrent disease within 6 months of completing adjuvant (...) esophageal cancer recurrent esophageal cancer adenocarcinoma of the stomach adenocarcinoma of the esophagus Additional relevant MeSH terms: Layout table for MeSH terms Adenocarcinoma Stomach Neoplasms Esophageal Neoplasms Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Digestive System Diseases Gastrointestinal Diseases Stomach Diseases Head and Neck Neoplasms Esophageal Diseases

2001 Clinical Trials

13926. BMS-247550 in Treating Patients With Metastatic Stomach Cancer Previously Treated With Chemotherapy

Sponsor: Bristol-Myers Squibb Collaborator: National Cancer Institute (NCI) Information provided by: Bristol-Myers Squibb Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have metastatic stomach cancer previously treated with chemotherapy. Condition or disease Intervention/treatment Phase (...) table for MeSH terms Adenocarcinoma Stomach Neoplasms Esophageal Neoplasms Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Digestive System Diseases Gastrointestinal Diseases Stomach Diseases Head and Neck Neoplasms Esophageal Diseases

2001 Clinical Trials

13927. Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer

cancer except localized basal cell or squamous cell skin cancer unless disease free for at least 5 years No major medical or psychiatric illness that would preclude study completion, compliance, or follow-up PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy No prior chemotherapy for prostate cancer Endocrine therapy No prior androgen-deprivation therapy Radiotherapy No prior pelvic radiotherapy No prior prostate brachytherapy Surgery No prior bilateral orchiectomy No prior radical (...) , 2015 Last Verified: December 2015 Keywords provided by Memorial Sloan Kettering Cancer Center: adenocarcinoma of the prostate stage III prostate cancer Additional relevant MeSH terms: Layout table for MeSH terms Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Neoplasms Genital Diseases, Male Prostatic Diseases Androgens Goserelin Bicalutamide Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Antineoplastic Agents

2003 Clinical Trials

13928. Suppression of Ovarian Function and Either Tamoxifen or Exemestane With or Without Chemotherapy in Treating Premenopausal Women With Resected Breast Cancer

prior or concurrent invasive malignancy except adequately treated basal cell or squamous cell skin cancer, nonbreast carcinoma in situ without invasion, contralateral or ipsilateral carcinoma in situ of the breast No prior or concurrent nonbreast invasive malignancy within the past 5 years that is nonrecurrent including any of the following: Stage I papillary thyroid cancer Stage Ia carcinoma of the cervix Stage Ia or b endometrioid endometrial cancer Borderline or stage I ovarian cancer No other (...) ., lumpectomy, quadrantectomy, or partial mastectomy with margins clear* of invasive cancer and ductal carcinoma in situ) followed by radiotherapy NOTE: *If all other margins are clear, a positive posterior (deep) margin is permitted, provided the excision was performed down to the pectoral fascia and all tumor has been removed OR a positive anterior (superficial; abutting skin) margin is allowed provided all tumor was removed Prior axillary lymph node dissection or negative axillary sentinel node biopsy

2003 Clinical Trials

13929. Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

effective nonhormonal contraception No history of noncompliance to medical regimens No other nonmalignant systemic disease that would preclude prolonged follow-up No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, nonbreast carcinoma in situ, contralateral or ipsilateral carcinoma in situ of the breast, or other nonrecurrent invasive nonbreast malignancy, including any of the following: Stage I papillary thyroid cancer Stage IA carcinoma (...) -regional axillary disease Prior surgery for primary breast cancer of 1 of the following types: Total mastectomy with or without adjuvant radiotherapy Breast-conserving procedure (e.g., lumpectomy, quadrantectomy, or partial mastectomy with margins negative* for invasive disease and ductal carcinoma in situ) with planned radiotherapy NOTE: *If all other margins are clear a positive posterior (deep) margin is permitted, provided the excision was performed down to the pectoral fascia and all tumor has

2003 Clinical Trials

13930. Suppression of Ovarian Function Plus Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

ipsilateral or contralateral invasive breast cancer; patients with synchronous bilateral invasive breast cancer (diagnosed histologically within 2 months) are eligible if the bilateral disease meets all other eligibility criteria Patients with previous or concomitant invasive malignancy are not eligible; the exceptions are patients with the following (and only the following) malignancies (previous or concomitant) who are eligible if adequately treated: Basal or squamous cell carcinoma of the skin In situ (...) tamoxifen alone in preventing the recurrence of hormone-responsive breast cancer. PURPOSE: This randomized phase III trial studies ovarian suppression with either tamoxifen or exemestane to see how well they work compared to tamoxifen alone in treating premenopausal women who have undergone surgery for hormone-responsive breast cancer. Condition or disease Intervention/treatment Phase Estrogen Receptor Positive Breast Cancer Progesterone Receptor Positive Tumor Recurrent Breast Carcinoma Stage IA Breast

2003 Clinical Trials

13931. Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer

of myocardial infarction No history of stroke No uncontrolled high blood pressure Other No uncontrolled metabolic or endocrine disease No malabsorption syndrome No known hypersensitivity to exemestane or its excipients No other malignancy within the past 5 years except curatively treated squamous cell or basal cell skin cancer or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy No prior immunotherapy No concurrent immunotherapy Chemotherapy No prior chemotherapy No concurrent (...) ( NCIC Clinical Trials Group ): breast cancer Additional relevant MeSH terms: Layout table for MeSH terms Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Exemestane Antineoplastic Agents Aromatase Inhibitors Steroid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Estrogen Antagonists Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs

2003 Clinical Trials

13932. Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer

Verified: September 2012 Keywords provided by European Organisation for Research and Treatment of Cancer - EORTC: penile squamous cell carcinoma stage III penile cancer stage IV penile cancer Additional relevant MeSH terms: Layout table for MeSH terms Penile Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Neoplasms Genital Diseases, Male Penile Diseases Cisplatin Irinotecan Antineoplastic Agents Topoisomerase I Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular (...) Volunteers: No Criteria DISEASE CHARACTERISTICS: Histologically confirmed penile squamous cell carcinoma Locally advanced or metastatic disease T3, N1-2 OR T4, N3, M1 Measurable disease outside of any previously irradiated field No clinical signs of brain metastases PATIENT CHARACTERISTICS: Age 75 and under Performance status WHO 0-2 Life expectancy Not specified Hematopoietic Absolute neutrophil count at least 2,000/mm^3 Platelet count at least 100,000/mm^3 Hepatic Bilirubin no greater than 1.5 times

2003 Clinical Trials

13933. S0030: Capecitabine in Treating Older Patients W/Metastatic or Recurrent Colorectal Cancer That Cannot Be Surgically Removed

than 2 times ULN Creatinine clearance greater than 50 mL/min Other Not pregnant or nursing Fertile patients must use effective contraception HIV negative No known seizure disorder No other malignancy except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, adequately treated stage I or II cancer currently in complete remission, or any other cancer for which the patient has been disease free for 5 years PRIOR CONCURRENT THERAPY: Biologic therapy (...) : Completed First Posted : January 27, 2003 Last Update Posted : January 3, 2013 Sponsor: Southwest Oncology Group Collaborator: National Cancer Institute (NCI) Information provided by (Responsible Party): Southwest Oncology Group Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating older patients who have

2002 Clinical Trials

13934. Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer

may make the tumor cells more sensitive to radiation therapy and may kill more tumor cells. Phase I trial to study the maximum tolerated dose (MTD) of combining erlotinib with docetaxel and radiation therapy in treating patients who have locally advanced head and neck cancer Condition or disease Intervention/treatment Phase Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma Stage III Squamous Cell Carcinoma of the Hypopharynx Stage III Squamous Cell Carcinoma of the Larynx (...) is treated on this protocol HIV positive patients are excluded from participation Patients with history of any other malignancy (except squamous cell or basal cell cancer of the skin or CIS of cervix) are ineligible unless a period of 5 years has elapsed since treatment of the previous cancer and the patient has remained continuously disease free Patients who are felt to be poorly compliant Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you

2002 Clinical Trials

13935. Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat Cancer

to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining erlotinib with radiation therapy with or without cisplatin may kill more tumor cells. Condition or disease Intervention/treatment Phase Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity Stage II Squamous Cell Carcinoma of the Oropharynx Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity Stage III Squamous Cell Carcinoma of the Oropharynx Stage (...) if disease free interval >= 3 years; basal cell carcinomas of the skin and in situ cervical dysphagias are allowed within this three year interval if completely resected Documentation of evaluable tumor less than or equal to four weeks before treatment start ECOG performance status = 0, 1 or 2 (Karnofsky >= 60%) Life expectancy of greater than or equal to 6 months Leukocytes >= 3,000 Absolute neutrophil count >= 1,500 Platelets >= 100,000 Total bilirubin within normal institutional limits unless due

2002 Clinical Trials

13936. Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer

Creatinine clearance at least 60 mL/min LVEF normal No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No other invasive malignancies within the past 5 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix No prior allergic reactions attributed to compounds of similar chemical or biological composition to tipifarnib or other agents used in the study (e.g., imidazoles or quinolones) No ongoing or active infection (...) to Layout table for additonal information Responsible Party: National Cancer Institute (NCI) ClinicalTrials.gov Identifier: Other Study ID Numbers: NCI-2012-02500 02-05-125 AECM-0205125 NCI-5598 CDR0000257811 First Posted: January 27, 2003 Last Update Posted: June 6, 2013 Last Verified: June 2013 Additional relevant MeSH terms: Layout table for MeSH terms Breast Neoplasms Inflammatory Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Cyclophosphamide Doxorubicin Liposomal

2002 Clinical Trials

13937. Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

within the past 5 years except previously excised and inactive basal cell or squamous cell skin cancer No prior allergic reactions attributed to compounds of similar chemical or biological composition to erlotinib or other study drugs (e.g., epidermal growth factor inhibitors like cetuximab) No significant traumatic injury within the past 3 weeks No peripheral neuropathy grade 2 or greater No ongoing or active infection No other uncontrolled concurrent illness that would preclude study entry (...) Sloan Kettering Cancer Center Collaborator: National Cancer Institute (NCI) Information provided by: National Cancer Institute (NCI) Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Combining erlotinib with combination chemotherapy may kill more tumor cells. PURPOSE: Phase I/II

2002 Clinical Trials

13938. A Study With Tarceva and Chemotherapy vs. Chemotherapy Alone in Patients With Advanced Lung Cancer

>= 3 weeks since any prior surgery or radiotherapy (>=2 weeks for patients who receive <=30 Gy of radiotherapy involving <25% of the marrow reserve) Use of an effective means of contraception (women of childbearing potential) Able to comply with study and follow-up procedures Exclusion Criteria: Evidence of small cell, carcinoid, or mixed small cell/non-small cell histology Malignancies within 3 years except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin (...) for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Signed informed consent Age >=18 years Histologically documented, unresectable, inoperable, locally advanced, recurrent or metastatic Stage IIIB or Stage IV Non-Small Cell Lung Cancer (NSCLC) A cytologic diagnosis is acceptable (i.e., FNA or pleural fluid cytology) Measurable or non-measurable disease ECOG performance status of 0 or 1 Life expectancy of >=3 months

2002 Clinical Trials

13939. Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy

antibody titers to autoimmune diseases Rheumatoid factor positive allowed unless ANA titer is greater than 1:80 and there is a history of or clinical signs or symptoms of connective tissue disease No active infection Other No other active malignancy within the past 5 years except adequately treated squamous cell or basal cell skin cancer, carcinoma in situ of the cervix, or superficial bladder cancer Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception (...) cells. PURPOSE: This phase II trial is studying anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody to see how well it works in treating patients with lymphoma or colon cancer that has not responded to vaccine therapy. Condition or disease Intervention/treatment Phase Lymphoma Biological: ipilimumab Phase 1 Detailed Description: OBJECTIVES: Primary Determine the toxicity of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody in patients with follicular or mantle

2002 Clinical Trials

13940. Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer

) OR Tumor greater than 3 cm with no invasion of mediastinal structures and no adenopathy greater than 1 cm (T3, N0, M0) Epidermoid carcinoma or adenocarcinoma Previously untreated Deemed resectable with curative intent No carcinoma in situ No small cell anaplastic carcinoma (i.e., chromogranin negative) No small cell neuroendocrine carcinoma (i.e., chromogranin positive) No multifocal esophageal carcinoma (i.e., 2 or more distinct lesions 5 or more cm apart) No involvement of the pharyngoesophageal (...) basal cell skin cancer or carcinoma in situ of the cervix Not pregnant Fertile patients must use effective contraception during and for 3 months after completion of chemotherapy PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy Not specified Endocrine therapy Not specified Radiotherapy Not specified Surgery Not specified Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research

2002 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>